PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy

Biomaterials

Volumn 34, Issue 1, 2013, Pages 196-208

  Gu, Guangzhi ^a   Xia, Huimin ^a,c   Hu, Quanyin ^a   Liu, Zhongyang ^a   Jiang, Mengyin ^d   Kang, Ting ^a   Miao, Deyu ^d   Tu, Yifan ^a   Pang, Zhiqing ^a   Song, Qingxiang ^b   Yao, Lei ^b   Chen, Hongzhan ^b   Gao, Xiaoling ^b   Chen, Jun ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c SHANGHAI INSTITUTE FOR FOOD AND DRUG CONTROL   (China)

^d SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Activatable cell penetrating peptide; Anti glioblastoma; Chemotherapy; Drug delivery system; Nanoparticle; Paclitaxel

Indexed keywords

ANTI-GLIOBLASTOMA; BIODISTRIBUTIONS; C6 CELLS; CELL-PENETRATING PEPTIDE; DRUG DELIVERY SYSTEM; ENERGY DEPENDENT; GLIOBLASTOMAS; IN-VITRO; IN-VIVO; IN-VIVO IMAGING; LOW MOLECULAR WEIGHT; MATRIX METALLOPROTEINASES; NUDE MICE; PACLITAXEL; TUMOR PENETRATION; TUMOR SPHEROID; UPREGULATED EXPRESSION;

CHEMOTHERAPY; DRUG DELIVERY; MOLECULAR BIOLOGY; MOLECULAR WEIGHT; NANOPARTICLES; PARTICLE SIZE ANALYSIS; ZETA POTENTIAL;

TUMORS;

COPOLYMER; GELATINASE A; GELATINASE B; MACROGOL; NANOPARTICLE; PACLITAXEL; POLYCAPROLACTONE; PROTAMINE; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER THERAPY; CONJUGATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; GLIOBLASTOMA; LIPID RAFT; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PINOCYTOSIS; PRIORITY JOURNAL; ZETA POTENTIAL;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; COUMARINS; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; ETHYLENE OXIDE; GLIOBLASTOMA; KAPLAN-MEIER ESTIMATE; LACTONES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; MOLECULAR WEIGHT; NANOPARTICLES; PACLITAXEL; PROTAMINES; RATS; RATS, SPRAGUE-DAWLEY; SPHEROIDS, CELLULAR; TISSUE DISTRIBUTION;

ANIMALIA; MUS MUSCULUS;

EID: 84868121994     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.09.044     Document Type: Article

References (51)

1. Kim W.Y., Lee H.Y. Brain angiogenesis in developmental and pathological processes: mechanism and therapeutic intervention in brain tumors. FEBS J 2009, 276:4653-4664.
2. Ong B.Y., Ranganath S.H., Lee L.Y., Lu F., Lee H.S., Sahinidis N.V., et al. Paclitaxel delivery from PLGA foams for controlled release in post-surgical chemotherapy against glioblastoma multiforme. Biomaterials 2009, 30:3189-3196.
3. Groothuis D.R. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro Oncol 2000, 2:45-59.
4. Jain R.K., Di Tomaso E., Duda D.G., Loeffler J.S., Sorensen A.G., Batchelor T.T. Angiogenesis in brain tumours. Nat Rev Neurosci 2007, 8:610-622.
5. Liu Y., Lu W.Y. Recent advances in brain tumor-targeted nano-drug delivery systems. Expert Opin Drug Deliv 2012, 9:671-686.
6. Jain K.K. Use of nanoparticles for drug delivery in glioblastoma multiforme. Expert Rev Neurother 2007, 7:363-372.
7. Beduneau A., Saulnier P., Benoit J.P. Active targeting of brain tumors using nanocarriers. Biomaterials 2007, 28:4947-4967.
8. Takara K., Hatakeyama H., Ohga N., Hida K., Harashima H. Design of a dual-ligand system using a specific ligand and cell penetrating peptide, resulting in a synergistic effect on selectivity and cellular uptake. Int J Pharm 2010, 396:143-148.
9. Koren E., Torchilin V.P. Cell-penetrating peptides: breaking through to the other side. Trends Mol Med 2012, 18:385-393.
10. Fonseca S.B., Pereira M.P., Kelley S.O. Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Deliv Rev 2009, 61:953-964.
11. Choi Y.S., Lee J.Y., Suh J.S., Kwon Y.M., Lee S.J., Chung J.K., et al. The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine. Biomaterials 2010, 31:1429-1443.
12. Lee L.M., Chang L.C., Wrobleski S., Wakefield T.W., Yang V.C. Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): preliminary in vivo evaluation of efficacy and toxicity using a canine model. Aaps Pharmsci 2001, 3:E19.
13. Liang J.F., Zhen L., Chang L.C., Yang V.C. A less toxic heparin antagonist-low molecular weight protamine. Biochemistry (Mosc) 2003, 68:116-120.
14. Tsui B., Singh V.K., Liang J.F., Yang V.C. Reduced reactivity towards anti-protamine antibodies of a low molecular weight protamine analogue. Thromb Res 2001, 101:417-420.
15. Zhang X.X., Eden H.S., Chen X. Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates. J Control Release 2012, 159:2-13.
16. Jiang T., Olson E.S., Nguyen Q.T., Roy M., Jennings P.A., Tsien R.Y. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci U S A 2004, 101:17867-17872.
17. Aguilera T.A., Olson E.S., Timmers M.M., Jiang T., Tsien R.Y. Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. Integr Biol (Camb) 2009, 1:371-381.
18. Forsyth P.A., Wong H., Laing T.D., Rewcastle N.B., Morris D.G., Muzik H., et al. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer 1999, 79:1828-1835.
19. Wang M., Wang T., Liu S., Yoshida D., Teramoto A. The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades. Brain Tumor Pathol 2003, 20:65-72.
20. Tauro J.R., Gemeinhart R.A. Matrix metalloprotease triggered delivery of cancer chemotherapeutics from hydrogel matrixes. Bioconjug Chem 2005, 16:1133-1139.
21. Chau Y., Tan F.E., Langer R. Synthesis and characterization of dextran-peptide-methotrexate conjugates for tumor targeting via mediation by matrix metalloproteinase II and matrix metalloproteinase IX. Bioconjug Chem 2004, 15:931-941.
22. Olson E.S., Jiang T., Aguilera T.A., Nguyen Q.T., Ellies L.G., Scadeng M., et al. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc Natl Acad Sci U S A 2010, 107:4311-4316.
23. Ke X.Y., Zhao B.J., Zhao X., Wang Y., Huang Y., Chen X.M., et al. The therapeutic efficacy of conjugated linoleic acid - paclitaxel on glioma in the rat. Biomaterials 2010, 31:5855-5864.
24. Xin H.L., Jiang X.Y., Gu J.J., Sha X.Y., Chen L.C., Law K., et al. Angiopep-conjugated poly(ethylene glycol)-co-poly(epsilon-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. Biomaterials 2011, 32:4293-4305.
25. Régina A., Demeule M., Ché C., Lavallée I., Poirier J., Gabathuler R., et al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol 2008, 155:185-197.
26. Zhan C.Y., Gu B., Xie C., Li J., Liu Y., Lu W.Y. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. J Control Release 2010, 143:136-142.
27. Singla A.K., Garg A., Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2002, 235:179-192.
28. Xia H.M., Gao X.L., Gu G.Z., Liu Z.Y., Zeng N., Hu Q.Y., et al. Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration. Biomaterials 2011, 32:9888-9898.
29. Zhang W., Shi Y., Chen Y.Z., Ye J., Sha X.Y., Fang X.L. Multifunctional Pluronic P123/F127 mixed polymeric micelles loaded with paclitaxel for the treatment of multidrug resistant tumors. Biomaterials 2011, 32:2894-2906.
30. Jiang X.Y., Sha X.Y., Xin H.L., Chen L.C., Gao X.H., Wang X., et al. Self-aggregated pegylated poly (trimethylene carbonate) nanoparticles decorated with c(RGDyK) peptide for targeted paclitaxel delivery to integrin-rich tumors. Biomaterials 2011, 32:9457-9469.
31. Zeng N., Hu Q.Y., Liu Z.Y., Gao X.L., Hu R.K., Song Q.X., et al. Preparation and characterization of paclitaxel-loaded DSPE-PEG-liquid crystalline nanoparticles (LCNPs) for improved bioavailability. Int J Pharm 2012, 424:58-66.
32. He H., Li Y., Jia X.R., Du J., Ying X., Lu W.L., et al. PEGylated Poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors. Biomaterials 2011, 32:478-487.
33. Guo J.W., Gao X.L., Su L.N., Xia H.M., Gu G.Z., Pang Z.Q., et al. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials 2011, 32:8010-8020.
34. Xia H.M., Gao X.L., Gu G.Z., Liu Z.Y., Hu Q.Y., Tu Y.F., et al. Penetratin-functionalized PEG-PLA nanoparticles for brain drug delivery. Int J Pharm 2012, 436:840-850.
35. Mohyeldin A., Chiocca E.A. Gene and viral therapy for glioblastoma: a review of clinical trials and future directions. Cancer J 2012, 18:82-88.
36. Qin Y., Chen H.L., Zhang Q.Y., Wang X.X., Yuan W.M., Kuai R., et al. Liposome formulated with TAT-modified cholesterol for improving brain delivery and therapeutic efficacy on brain glioma in animals. Int J Pharm 2011, 420:304-312.
37. Chen Y., Liu L.H. Modern methods for delivery of drugs across the blood-brain barrier. Adv Drug Deliv Rev 2012, 64:640-665.
38. Herve F., Ghinea N., Scherrmann J.M. CNS delivery via adsorptive transcytosis. AAPS J 2008, 10:455-472.
39. Chawla J.S., Amiji M.M. Biodegradable poly(epsilon -caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen. Int J Pharm 2002, 249:127-138.
40. Hu K.L., Li J.W., Shen Y.H., Lu W., Gao X.L., Zhang Q.Z., et al. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J Control Release 2009, 134:55-61.
41. Li S.D., Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 2008, 5:496-504.
42. Chekhonin V.P., Baklaushev V.P., Yusubalieva G.M., Pavlov K.A., Ukhova O.V., Gurina O.I. Modeling and immunohistochemical analysis of C6 glioma in vivo. Bull Exp Biol Med 2007, 143:501-509.
43. Takahashi M., Fukami S., Iwata N., Inoue K., Itohara S., Itoh H., et al. In vivo glioma growth requires host-derived matrix metalloproteinase 2 for maintenance of angioarchitecture. Pharmacol Res 2002, 46:155-163.
44. Esteve P.O., Robledo O., Potworowski E.F., St-Pierre Y. Induced expression of MMP-9 in C6 glioma cells is inhibited by PDGF via a PI 3-kinase-dependent pathway. Biochem Biophys Res Commun 2002, 296:864-869.
45. Yong V.W., Power C., Forsyth P., Edwards D.R. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2001, 2:502-511.
46. Funovics M., Weissleder R., Tung C.H. Protease sensors for bioimaging. Anal Bioanal Chem 2003, 377:956-963.
47. Song Q.X., Yao L., Huang M., Hu Q.Y., Lu Q., Wu B.X., et al. Mechanisms of transcellular transport of wheat germ agglutinin-functionalized polymeric nanoparticles in Caco-2 cells. Biomaterials 2012, 33:6769-6782.
48. Gao X.L., Wang T., Wu B.X., Chen J., Chen J.Y., Yue Y., et al. Quantum dots for tracking cellular transport of lectin-functionalized nanoparticles. Biochem Biophys Res Commun 2008, 377:35-40.
49. Xin H.L., Sha X.Y., Jiang X.Y., Chen L.C., Law K., Gu J.J., et al. The brain targeting mechanism of Angiopep-conjugated poly(ethylene glycol)-co-poly(epsilon-caprolactone) nanoparticles. Biomaterials 2012, 33:1673-1681.
50. Nam H.Y., Kwon S.M., Chung H., Lee S.Y., Kwon S.H., Jeon H., et al. Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles. J Control Release 2009, 135:259-267.
51. Gao H.L., Qian J., Yang Z., Pang Z.Q., Xi Z.J., Cao S.J., et al. Whole-cell SELEX aptamer-functionalised poly(ethyleneglycol)-poly(epsilon-caprolactone) nanoparticles for enhanced targeted glioblastoma therapy. Biomaterials 2012, 33:6264-6272.